In a vaccinia virus clinical trial, JX-594 treatment of hepatocellular cancers led to quantifiable, circulating GM-CSF levels in 69% of the patients receiving 109 plaque forming units of virus36. This evidence concerns the gene CSF2 and hepatocellular carcinoma.